Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06120491 · ClinicalTrials.gov registry record · Phase 3

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

A Phase 3 study of Metastatic Castration-Sensitive Prostate Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
1,800
Enrollment target
20
Study locations

NCT06120491 is a Phase 3 study of Metastatic Castration-Sensitive Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,800 participants, above the 204-participant average among 5 other Metastatic Castration-Sensitive Prostate Cancer trials with a reported enrollment target (782% higher). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06120491, a Phase 3 study of Metastatic Castration-Sensitive Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
1,800 participants
Enrollment target
20
Study locations

Study Summary

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Conditions Studied

Metastatic Castration-Sensitive Prostate Cancer

Interventions

  • DRUG Placebo
  • DRUG Darolutamide
  • DRUG Enzalutamide
  • DRUG Abiraterone Acetate
  • DRUG Saruparib

Study Locations (20)

California

  • Research Site - Bakersfield
  • Research Site - Fountain Valley
  • Research Site - Fullerton
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Montebello
  • Research Site - Pasadena
  • Research Site - Pomona
  • Research Site - Sacramento
  • Research Site - San Diego
  • Research Site - San Francisco
  • Research Site - Santa Barbara
  • Research Site - Santa Monica
  • Research Site - Santa Rosa

Arizona

  • Research Site - Chandler
  • Research Site - Gilbert
  • Research Site - Phoenix
  • Research Site - Tucson

Arkansas

  • Research Site - Little Rock
  • Research Site - Springdale

Trial Details

FieldValue
Enrollment Target 1,800 participants
Start Date 2023-11-21
Est. Completion 2031-04-30
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06120491

The ClinicalTrials.gov registry entry for NCT06120491 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 204-participant average among 5 other Metastatic Castration-Sensitive Prostate Cancer trials with a reported enrollment target (782% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Sensitive Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT06120491 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06120491 about?

NCT06120491 is a clinical study titled "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents". The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

What is the current status of trial NCT06120491?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2023-11-21. Estimated completion is 2031-04-30.

What conditions does trial NCT06120491 study?

This clinical trial studies the following conditions: Metastatic Castration-Sensitive Prostate Cancer.

What interventions are being tested in trial NCT06120491?

The interventions under investigation include: Placebo (DRUG), Darolutamide (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG), Saruparib (DRUG).

Who is sponsoring clinical trial NCT06120491?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06120491 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Sensitive Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Sensitive Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.